Physician profile
Michael D Fox
NPI 1508859646
$1,147.27
in general payments reported to CMS, 2019-2025
20 companies · $70.84 in 2025
The $70.84 reported for 2025 was less than what a typical Reproductive Endocrinology provider received nationally (typical 2025 total: $140).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $422 · 2020: $217 · 2021: $54.72 · 2022: $171 · 2023: $211 · 2025: $70.84.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $282.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $282.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ferring Pharmaceuticals INC. | $231.66 | 2019-2023 | Menopur |
| Zimmer Biomet Holdings, INC. | $160.92 | 2023 | Persona |
| Coopersurgical, INC. | $127.00 | 2020-2022 | |
| Abbvie INC. | $125.98 | 2019 | |
| Braintree Laboratories, INC. | $106.64 | 2019 | |
| Organon LLC | $83.76 | 2021-2025 | Follistim Aq, Ganirelix Acetate, Pregnyl |
| Karl Storz Endoscopy-America | $44.14 | 2019 | |
| Merck Sharp & Dohme LLC | $39.05 | 2019-2020 | |
| Vertical Pharmaceuticals, LLC | $30.21 | 2019-2020 | |
| Acelrx Pharmaceuticals, INC. | $29.74 | 2019 | |
| Lilly USA, LLC | $21.49 | 2025 | Mounjaro |
| Duchesnay USA Incorporated | $19.14 | 2019 | |
| Covidien Lp | $18.99 | 2019 | |
| Hologic Sales and Service, LLC | $18.85 | 2022 | |
| Emd Serono, INC. | $18.55 | 2020 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Olympus America INC. | $18.21 | 2023 | Pneumoliner |
| Novo Nordisk INC | $15.22 | 2025 | Wegovy |
| Pfizer INC. | $13.51 | 2023 | |
| Boston Scientific Corporation | $12.61 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $11.60 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Fox listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.